

Revised: August 2017 (7th version)

Standard Commodity Classification No. of Japan

875200

- Kampo-preparation -

TEIKOKU Tokakujokito Extract Granules

< Tokakujokito >

Storage
Store at room temperature in a tight container. [See the "Precaution for handling" section.]

Approval No.	(61AM) 3655
Date of listing in the NHI reimbursement price	October 1987
Date of initial marketing in Japan	October 1987

Expiration date
Tokakujokito should be used before the expiration date indicated on the label and the package.

DESCRIPTION

Composition	7.5 g of TEIKOKU Tokakujokito Extract Granules contains 2.38 g of a dried water extract of the following mixed crude drugs.	
	JP Peach Kernel -----	5.0 g
	JP Cinnamon Bark -----	4.0 g
	JP Rhubarb -----	3.0 g
	JP Sodium Sulfate Hydrate -----	2.0 g
	JP Glycyrrhiza -----	1.5 g
	(JP: The Japanese Pharmacopoeia)	
Inactive ingredients	JP Lactose Hydrate	
	JP Microcrystalline Cellulose JP Magnesium Stearate	
Description	Dosage form	Granules
	Color	Light brown
	Smell	Characteristic smell
	Taste	Saline, subsequently sweet and bitter
	ID code	TEIKOKU 61

INDICATIONS

The following symptoms of those patients with a comparatively strong constitution and hot flashes who are likely to have constipation:

Menstrual irregularity, dysmenorrhea, anxiety during menstruation or following childbirth, low back pain, constipation, accessory symptoms associated with hypertension (headache, dizziness, and shoulder stiffness)

DOSAGE AND ADMINISTRATION

For oral use, the usual adult dosage is 2.5 g of TEIKOKU Tokakujokito Extract Granules three times daily before meals.

The dosage may be adjusted according to the patient's age, body weight, and symptoms.

PRECAUTIONS**1. Careful Administration (Tokakujokito should be administered with care in the following patients.)**

- (1) Patients with diarrhea or soft feces [These symptoms may be aggravated.]
- (2) Patients with an extremely weak gastrointestinal tract [Anorexia, epigastric distress, abdominal pain, diarrhea, etc. may occur.]
- (3) Patients with greatly declined constitution [Adverse reactions are likely to occur, and the symptoms may be aggravated.]

2. Important Precautions

- (1) When this product is used, the patient's "SHO" (constitution/symptoms) should be taken into account. The patient's progress should be carefully monitored, and if no improvement in symptoms/findings is observed, continuous treatment should be avoided.
- (2) Since this product contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc., and if any abnormality is observed, administration should be discontinued.
- (3) When this product is coadministered with other Kampo-preparations (Japanese traditional herbal medicines) etc., attention should be paid to the duplication of the contained crude drugs. Special caution should be exercised when this product is coadministered with preparations containing Rhubarb.
- (4) Since there is an individual difference in the cathartic action of Rhubarb, caution should be exercised concerning the dosage and administration.

SHO : The term "SHO" refers to a particular pathological status of a patient evaluated by the Kampo diagnosis, and is patterned according to the patient's constitution, symptoms, etc. Kampo-preparations (Japanese traditional herbal medicines) should be used after confirmation that it is suitable for the identified "SHO" of the patient.

3. Drug Interactions

Precautions for coadministration (Tokakujokito should be administered with care when coadministered with the following drugs.)

Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
Preparations containing Glycyrrhiza	Pseudoaldosteronism is likely to occur. Besides, myopathy is likely to occur as a result of hypokalemia. (Refer to the section "Clinically significant adverse reactions".)	Since glycyrrhizinic acid has an accelerating action on the potassium excretion at the renal tubules, an acceleration of decrease in the serum potassium level has been suggested.
Preparations containing glycyrrhizinic acid or glycyrrhizinates		

4. Adverse Reactions

This product has not been investigated (drug use investigations, etc.) to determine the incidence of adverse reactions. Therefore, the incidence of adverse reactions is not known.

(1) Clinically significant adverse reactions

1) Pseudoaldosteronism: Pseudoaldosteronism such as hypokalemia, increased blood pressure, retention of sodium/body fluid, edema, increased body weight, etc. may occur. The patient should be carefully monitored (measurement of serum potassium level, etc.), and if any abnormality is observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.

2) Myopathy: Myopathy may occur as a result of hypokalemia. The patient should be carefully monitored, and if any abnormality such as weakness, convulsion/paralysis of limbs, etc. are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.

(2) Other adverse reactions

	Incidence unknown
Hypersensitivity ^{Note)}	Rash, Redness, Pruritus, etc.
Gastrointestinal	Anorexia, Epigastric distress, Abdominal pain, Diarrhea, etc.

Note) If such symptoms are observed, administration should be discontinued.

5. Use in the Elderly

Because elderly patients often have reduced physiological function, careful supervision and measures such as reducing the dose are recommended.

6. Use during Pregnancy, Delivery or Lactation

(1) Use of this product in pregnant women, women who may possibly be pregnant is not recommended. [Rhubarb (uterotonic action and congestive action on the intrapelvic organs), Sodium Sulfate (uterotonic action), Peach Kernel contained in this product may cause premature birth or abortion.]

(2) This product should be administered with care in nursing mothers. [Anthraquinone derivatives in Rhubarb contained in this product may be excreted in breast milk and induce diarrhea in nursing infants.]

7. Pediatric Use

The safety of this product in children has not been established. [Insufficient clinical data.]

8. Other Precautions

This product contains Sodium Sulfate. Caution should be exercised when continuous treatment with this product is given to patients who need limited salt-intake therapeutically.

PRECAUTIONS FOR HANDLING

1. This product should not be stored in direct rays and should be stored in a cool place with, if possible, little humidity.
2. Since it is hygroscopic property, this product should not be stored in humid places after opening.

PACKAGING

- Bottles of 500 g
- Boxes of 2.5 g× 42 packets
- Boxes of 2.5 g×252 packets

REQUEST FOR LITERATURE SHOULD BE MADE TO:

Product Information Unit,
Pharmaceutical Sales & Marketing Dept.
Teikoku Seiyaku Co., Ltd.
6-6 Nihonbashi-kobunacho, Chuo-Ku, Tokyo
103-0024, Japan
Tel 0120-189-567

Manufactured by:

Teikoku Kampo Seiyaku Co., Ltd.
80-11 Kitahara, Donari, Donari-cho, Awa, Tokushima
771-1506, Japan

Distributed by:

Teikoku Seiyaku Co., Ltd.
567, Sanbonmatsu, Higashikagawa, Kagawa
769-2695, Japan